Analytical validation of telomerase activity for cancer early detection: TRAP/PCR-CE and hTERT mRNA quantification assay for high-throughput screening of tumor cells

Journal of Molecular Diagnostics

Volumn 6, Issue 3, 2004, Pages 157-165

  Jakupciak, John P ^a   Wang, Wendy ^b   Barker, Peter E ^a   Srivastava, Sudhir ^b   Atha, Donald H ^a  

^a NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CELL EXTRACT; MESSENGER RNA; PRIMER RNA; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE;

ANALYTIC METHOD; ANALYTICAL EQUIPMENT; ARTICLE; AUTOMATION; CANCER CELL CULTURE; CANCER CENTER; CANCER DIAGNOSIS; CAPILLARY ELECTROPHORESIS; CATALYSIS; CELL ISOLATION; CONTROLLED STUDY; EARLY DIAGNOSIS; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME SUBUNIT; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA PROBE; ROBOTICS; SENSITIVITY ANALYSIS; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; TUMOR CELL; VALIDATION PROCESS;

EID: 4344614197     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-1578(10)60506-5     Document Type: Article

References (34)

1. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015
2. Shay JW, Bacchetti S: A survey of telomerase activity in human cancer. Eur J Cancer 1997, 33:787-791
3. Arai T, Yasuda Y, Takaya T, Ito Y, Hayalkawa K, Toshima S, Shibuya C, Yoshima N, Kashiki Y: Application of telomerase activity for screening of primary lung cancer in broncho-alveolar lavage fluid. Oncol Rep 1998, 5:405-408
4. Asai A, Kiyozuka Y, Yoshida R, Fujii T, Hioki K, Tsubura A: Telomere length, telomerase activity, and telomerase RNA expression in human esophageal cancer cells: correlation with cell proliferation, differentiation, and chemosensitivity to anticancer drugs. Anticancer Res 1998, 18:1465-1472
5. Engelhardt M, Drullinsky P, Guillem J, Moore M: Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer. Clin Cancer Res 1997, 11:1931-1941
6. Dome JS, Chung S, Bergemann T, Umbricht CB, Saji M, Carey LA, Grundy PE, Perlman EJ, Breslaw NE, Sukumar S: High telomerase reverse transcriptase (hTERT) messenger RNA level correlates with tumor recurrence in patients with favorable histology Wilms' tumor. Cancer Res 1999, 59:4301-4307
7. Herbert BS, Pitts AE, Baker SI, Hamilton SE, Wright WE, Shay JW, Corey DR: Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc Natl Acad Sci USA 1999, 96:14276-14281
8. Shay JW: Telomerase and cancer. Molecular Pathology of Early Cancer. Edited by Srivastava S, Hensen DE, Gazdar A. Washington, DC, IOS Press, 1999, pp 405-424
9. Stampfer MR, Garbe J, Levine G, Lichsteiner S, Vasserot AP, Yaswen P: expression of telomerase catalytic subunit, hTERT, induces resistance to transforming growth factor B, growth inhibition in p16 human mammary epithelial cells. Proc Natl Acad Sci USA 2001, 98:4498-4503
10. Belair CD, Yeager TR, Lopez PM, Reznikoff CA: Telomerase activity: a biomarker of cell proliferation, not malignant transformation. Proc Natl Acad Sci USA 1997, 94:13677-13682
11. Shay JW, Gazdar AF: Telomerase in the early detection of cancer. J Clin Pathol 1997, 50:106-109
12. Hess JL, Highsmith WE: Telomerase detection in body fluids. Clin Chem 2002, 48:18-24
13. Jin S, Zhang W, Teng M: Clinical implications of telomerase activity in breast cancer fine-needle aspirates. Zhonghua Zhong Liu Za Zhi 2000, 22:132-134
14. Strovel JW, Abruzzo VL, Highsmith WE, Stamberg J: Quantitative measurement of telomerase activity in lymphadenopathy: correlation with histologic features and human immunodeficiency virus-1 infection. Mod Pathol 1998, 11:957-962
15. Meid FH, Gygi CM, Leisinger HJ, Bosman FT, Benhattar J: The use of telomerase activity for the detection of prostatic cancer cells after prostatic massage. J Urol 2001, 165:1802-1805
16. Sawant SG, Gregoire V, Dhar S, Umbricht CB, Cvilic S, Sukumar S, Pandita TK: Telomerase activity as a measure for monitoring radiocurability of tumor cells. FASEB J 1999, 13:1047-1054
17. Atha DH, Miller K, Sanow AD, Xu J, Hess JL, Wu OC, Wang W, Srivastava S, Highsmith WE: High-throughput analysis of telomerase by capillary electrophoresis. Electrophoresis 2003, 24:109-114
18. Hess JL, Atha DH, Xu J, Highsmith WE: Telomerase activity measurement in magnetically captured epithelial cells: comparison of slab-gel and capillary electrophoresis. Electrophoresis 2004, 25:1852-1859
19. Yi X, Shay JW, Wright WE: Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells. Nucleic Acids Res 2001, 29:4818-4825
20. Brandhorst BP, McConkey EH: Relationship between nuclear and cytoplasmic poly(adenylic acid). Proc Natl Acad Sci USA 1975, 72: 3580-3584
21. Emrich T, Chang SY, Karl G, Panzinger B, Santini C: Detection of telomerase components by quantitative real-time on-line PCR analysis with the LightCycler. Methods Mol Biol 2002, 191:99-108
22. Yi X, White DM, Aisner DL, Baur JA, Wright W, Shay JW: An alternate splicing variant of the telomerase catalytic subunit inhibits telomerase activity. Neoplasia 2000, 2:433-440
23. Colgin LM, Wilkinson C, Englezou A, Kilian A, Robinson MO, Reddel RR: The hTERT a splice variant is a dominant negative inhibitor of telomerase activity. Neoplasia 2000, 2:426-432
24. Ohyashiki JH, Ohyashiki K, Toyama K, Shay JW: A non-radioactive, fluorescence-based telomeric repeat amplification protocol to detect and quantitate telomerase activity. TIG 1996, 395-396
25. Srivastava S, Kramer BS: Early detection cancer research network. Lab Invest 2000, 80:1147-1148
26. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y: Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001, 93:1054-1061
27. Barker PE: Cancer biomarker validation: standards and process: roles for the National Institute of Standards and Technology (NIST). Ann NY Acad Sci 2003, 983:142-150
28. Xiao Y, Welch M, Semmes OJ, Barker P: NIST SRM 1951a as a prototype serum standard for human proteomics. Mol Cell Proteomics 2002, 1:691
29. Nooijer J, Lechner L, Cancel M, Vries H: A randomized controlled study of short term and long term effects of tailored information versus general information on intention and behaviour related to early detection of cancer. Cancer Epidemiol 2002, 11:1489-1491
30. Geisler SA, Olshan AF, Weissler MC, Cai J, Funkhouser WK, Smith J, Vick K: p16 and p53 protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer. Clin Cancer Res 2002, 8:3445-3453
31. Doyle LA, Hess J, Lu DM, Guo C, Lingam A, Hey JC, Krasna MJ, Highsmith WE: Association of telomerase expression in circulating lung cancer cells with disease-free and overall patient survival. Proc Am Soc Clin Oncol 2003, 22:847
32. Hayes RB, Smith CO, Huang WY, Read Y, Kopp WC: Whole blood cryopreservation in epidemiological studies. Cancer Epidemiol 2002, 11:1496-1498
33. Nakamura Y, Tahara E, Tahara H, Yasui W, Ide T: Quantitative reevaluation of telomerase activity in cancerous qnd non-cancerous gastrointestinal tissue. Mol Carcinog 1999, 26:312-320
34. Russo A, Migliavacca M, Zanna I, Valerie MR, Latteri MA, Grassi N, Pantuso G, Salerno S, Dardanoni G, Albanse I, Laferina M, Tomasino RM, Gebbia N, Bazan V: P53 mutations in L3 loop zinc binding domain, DNA ploidy, and S phase fraction are independent prognostic indicators in colorectal cancer. Cancer Epidemiol 2002, 11:1322-1331